ClinicalTrials.gg
Active, not recruitingNCT01879761Updated Jul 13, 2026

Immune Resolution After Staphylococcus Aureus Bacteremia

An observational study in Immune Response To Sepsis and Staphylococcus Aureus Infection, sponsored by University of Chicago. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by University of Chicago · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
102
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 125 studies in Staphylococcal Infections with a site in United States — 6 open to participants now, 11 under way, none of them phase 3. Staphylococcal Infections · United States.

Enrollment
23rd of 32
102 · median 217
Started
2013
with 7 others
Observational
33 of 125
2 open now
Primary completion
2027-06
later than 7 of 10 live
Registered
78th of 125
by date

Among the 125 studies in Staphylococcal Infections with a site in United States, this one is the 23rd largest by enrollment of the 32 observational ones that give a count, is one of 8 that started in 2013, is one of 33 observational ones, reaches primary completion later than 7 of the 10 other live ones, and was the 78th registered.

Staphylococcal Infections

305 studies on the registry are indexed under Staphylococcal Infections; 36 are open to participants now.

Browse Staphylococcal Infections studies →

Open to participants now

6 of the 125 studies in Staphylococcal Infections with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Staphylococcal Infections studies recruiting now, 16 (73%) set no upper age limit and 4 (18%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Staphylococcal Infections with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine how monocyte HLA-DR and other markers of immune function change with time in patients with and without prior immune dysfunction who survive sepsis from Staphylococcus aureus bacteremia.

We hypothesize that patients with prior immune dysfunction will have greater reductions in HLA-DR and other markers of immune function after an episode of sepsis than people who do not have prior immune dysfunction.

03

Conditions studied

  • Immune Response To Sepsis
  • Staphylococcus Aureus Infection

Keywords

  • Immunosuppressed
  • Sepsis
  • Staphylococcus Aureus
  • Bacteremia
  • HLA-DR
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Hospital inpatients with Staphylococcus aureus bacteremia who are over 18 years old.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least one blood culture positive for S. aureus
  • Patients aged ≥18 years
  • At least two of four systemic inflammatory response syndrome (SIRS) criteria on the day of positive blood cultures. SIRS criteria are:

    • Body temperature less than 36°C(96.8°F) or greater than 38°C(100.4°F)
    • Heart rate greater than 90 beats per minute
    • Tachypnea (high respiratory rate), with greater than 20 breaths per minute; or, an arterial partial pressure of carbon dioxide less than 32 mmHg
    • WBC less than 4000 cells/mm³ (4 x 109 cells/L) or greater than 12,000 cells/mm³ (12 x 109 cells/L); or the presence of greater than 10% immature neutrophils (band forms)

Exclusion criteria

Exclusion Criteria:

  • Sequential Organ Failure Assessment (SOFA) score > 12 on day of positive blood cultures
  • Survival expected to be \< 7 days from positive blood cultures
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
102 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Immunosuppressed

    Immunosuppressed includes patients with any one of the following: 1. a diagnosis of a hematological malignancy 2. a diagnosis of HIV 3. myelosuppressive chemotherapy in the previous 90 days 4. immune-modulating medications in the previous 90 days

  • Non-Immunosuppressed

    Subject does not fit immunosuppressed criteria

06

What researchers measure

Primary outcomes

  1. HLA-DR and cytokines

    Percent expression of HLA-DR on monocytes will be measured by flow cytometry. Cytokine levels will be measured by ELISA.

    Time frame: 0-30 days

Secondary outcomes

  1. New Infections

    Time frame: 0-90 days

Other outcomes

  1. Mortality

    Time frame: 0-90 days

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Jun 2027 and a completion of Jun 2027. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2013
First posted
Jun 18, 2013
Start
Jun 2013
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01879761
Responsible party
Sponsor
First posted
Jun 18, 2013
Start date
Jun 2013
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jul 13, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion